Role evidence
Usage summary
Strongest role: Inclusion Required
Inclusion-required count: 14
Treatment-assignment count: 0
Stratification count: 1
Trial Selection Rising
MET exon 14 skipping
ovarian cancer · Small Molecule Inhibitor
MET exon 14 skipping is flagged as trial selection rising because public trials show inclusion required evidence in 15 contexts. FDA CDx context should be reviewed manually.
Threshold snippets
Fragmentation view
Threshold count: 3
Common snippets: MSI-H | MSI-H | MSI-H
Threshold label: Moderate
FDA CDx context
Mapping summary
CDx label: Fda Cdx Context Not Found
CDx maturity score: 1/5
Confidence: High
Patent-density signal
Diagnostic appendix
Signal count: 0
Recent signals: 0
Density label: Low
Source links
Evidence paths
https://clinicaltrials.gov/study/NCT01012817 | https://clinicaltrials.gov/study/NCT01778803 | https://clinicaltrials.gov/study/NCT05467670 | https://clinicaltrials.gov/study/NCT01175343 | https://clinicaltrials.gov/study/NCT05200559 | https://clinicaltrials.gov/study/NCT02407509 | https://clinicaltrials.gov/study/NCT05043402 | https://clinicaltrials.gov/study/NCT06660511 | https://clinicaltrials.gov/study/NCT03598270 | https://clinicaltrials.gov/study/NCT04840589 | https://clinicaltrials.gov/study/NCT06600841 | https://clinicaltrials.gov/study/NCT03642132 | https://clinicaltrials.gov/study/NCT06976892 | https://clinicaltrials.gov/study/NCT04606914 | https://clinicaltrials.gov/study/NCT05001282